ERBB2 and breast cancer: Tucatinib is a potent, selective, and reversible HER2 tyrosine kinase inhibitor, approved in combination with trastuzumab and capecitabine for the treatment of unresectable, locally advanced, or metastatic HER2-positive BC based on phase III HER2CLIMB study.